The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Open accessAbstract
Cancer is one of the main causes of death worldwide. Despite the significant development of methods of cancer healing during the past decades, chemotherapy still remains the main method for cancer treatment. Depending on the mechanism of action, commonly used chemotherapeutic agents can be divided into several classes (antimetabolites, alkylating agents, mitotic spindle inhibitors, topoisomerase inhibitors, and others). Multidrug resistance (MDR) is responsible for over 90% of deaths in cancer patients receiving traditional chemotherapeutics or novel targeted drugs. The mechanisms of MDR include elevated metabolism of xenobiotics, enhanced efflux of drugs, growth factors, increased DNA repair capacity, and genetic factors (gene mutations, amplifications, and epigenetic alterations). Rapidly increasing numbers of biomedical studies are focused on designing chemotherapeutics that are able to evade or reverse MDR. The aim of this review is not only to demonstrate the latest data on the mechanisms of cellular resistance to anticancer agents currently used in clinical treatment but also to present the mechanisms of action of novel potential antitumor drugs which have been designed to overcome these resistance mechanisms. Better understanding of the mechanisms of MDR and targets of novel chemotherapy agents should provide guidance for future research concerning new effective strategies in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, L., Li, X., Cheng, M., Wang, S., Zheng, Q., & Liu, Q. (2018) · RSC Advances · doi:10.1039/c8ra09506j · Cited by 11
RetractedGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Fitzmaurice, C., & Global Burden of Disease Cancer Collaboration (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1568 · Cited by 1,646
Glutathione metabolism in cancer progression and treatment resistance
Bansal, A., & Simon, M. C. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201804161 · Cited by 1,233
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
Wu, Q., Yang, Z., Nie, Y., Shi, Y., & Fan, D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.013 · Cited by 776
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
Research works printed but not linked: 12
- Marchi, 2012, Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, Ther. Adv. Hematol., 3, 227, 10.1177/2040620712445330 · doi:10.1177/2040620712445330
- Le, T., Bhushan, V., Sochat, M., and Chavda, Y. (2017). First Aid for the USMLE Step 1, McGraw-Hill Education. [1st ed.].
- Mesci, 2019, The effect of ATP-binding cassette (ABC) transporters in human cancers, Int. J. Sci. Lett., 1, 1, 10.38058/ijsl.594000 · doi:10.38058/ijsl.594000
- Zu, 2014, Effects of P-glycoprotein and its inhibitors on apoptosis in K562 cells, Molecules, 19, 13061, 10.3390/molecules190913061 · doi:10.3390/molecules190913061
- Satake, 2015, Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens, Biomed. Mater. Eng., 25, 249
- Galski, 2013, P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway, Biochem Pharmacol., 86, 584, 10.1016/j.bcp.2013.06.004 · doi:10.1016/j.bcp.2013.06.004
- Zhou, 2017, Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling, Oncotarget, 8, 101965, 10.18632/oncotarget.21949 · doi:10.18632/oncotarget.21949
- Greenfield, G., McMullan, R., Robson, N., McGimpsey, J., Catherwood, M., and McMullin, M.F. (2019). Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia. BMC Hematol., 19. · doi:10.1186/s12878-019-0139-2
- Lin, 2015, Upregulation of microRNA-224 sensitizes human cervical cells SiHa to paclitaxel, Eur. J. Gynaecol. Oncol., 36, 432
- Chapman, 2015, Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF, Bioorg. Med. Chem. Lett., 25, 4097, 10.1016/j.bmcl.2015.08.031 · doi:10.1016/j.bmcl.2015.08.031
- Wu, 2010, Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma, Invest. New Drugs, 28, 670, 10.1007/s10637-009-9286-9 · doi:10.1007/s10637-009-9286-9
- Demir, 2018, Evaluation of chalcones as inhibitors of glutathione S-transferase, J. Biochem. Mol. Toxicol., 32, e22047, 10.1002/jbt.22047 · doi:10.1002/jbt.22047
Cited by
PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., Li, W., Hu, J., Lu, C., & Liu, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02998-6 · Cited by 923
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Kciuk, M., Marciniak, B., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144919 · Cited by 266
Self-citationHanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
Metadata
- Authors
- Bukowski, K., Kciuk, M., & Kontek, R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-02
- Volume
- 21
- Issue
- 9
- Pages
- 3233
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3021909056
- Cited by
- 1,757
- References
- 115
- FWCI
- 66.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of Multidrug Resistance in Cancer Chemotherapy. https://app.cochat.ai/papers/10.3390/ijms21093233
- The paper
- Bukowski, K., Kciuk, M., & Kontek, R. (2020). Mechanisms of Multidrug Resistance in Cancer Chemotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21093233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
